You are here:

ixekizumab (Taltz)

Advice

following a full submission:  

ixekizumab (Taltz®) is accepted for restricted use within NHS Scotland.

Indication under review: moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.

SMC restriction: patients who have failed to respond to standard systemic therapies (including ciclosporin, methotrexate and phototherapy), are intolerant to, or have a contra-indication to these treatments.

Ixekizumab was superior to placebo and to a tumour necrosis factor (TNF) antagonist for improving symptoms of adults with moderate to severe plaque psoriasis.  

This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of ixekizumab. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.

 

 

Drug Details

Drug Name: ixekizumab (Taltz)
SMC Drug ID: 1223/17
Manufacturer: Eli Lilly and Company Ltd
Indication: Moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
BNF Category:
Sub Category: 13.5 Preparations for eczema and psoriasis
Submission Type: Full submission
Status: Restricted
Date Advice Published: 10 April 2017

Back